z-logo
open-access-imgOpen Access
A krónikus myeloid leukaemia korszerű diagnosztikája és kezelése
Author(s) -
Judit Demeter,
Anna Poros,
Csaba Bödör,
Laura Horváth,
Tamás Masszi
Publication year - 2016
Publication title -
orvosi hetilap
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.176
H-Index - 21
eISSN - 1788-6120
pISSN - 0030-6002
DOI - 10.1556/650.2016.30521
Subject(s) - chronic myelogenous leukemia , myeloproliferative neoplasm , tyrosine kinase , cancer research , medicine , haematopoiesis , chromosomal translocation , dasatinib , leukemia , tyrosine kinase inhibitor , philadelphia chromosome , stem cell , cd135 , imatinib , nilotinib , myeloid leukemia , oncology , immunology , biology , bone marrow , myelofibrosis , cancer , genetics , gene , receptor
Chronic myelogenous leukemia is a clonal myeloproliferative neoplasm caused by reciprocal translocation involving chromosomes 9 and 22 resulting in the expression of a constitutively activated BCR-ABL1 tyrosine kinase that leads to the malignant transformation of the hematopoietic stem cells. The condition was previously known as a relentlessly progressive disease, but the treatment was revolutionalized by the efficacy of tyrosine kinase inhibitors. Therapeutic success is thus currently determined by the depth of molecular response achieved on therapy. Multiple tyrosine kinase agents are available even for the first line treatment. This guideline summarizes current focal points of the treatment of chronic myelogenous leukemia specific to Hungary and provides definitions for optimal molecular responses in this condition. Orv. Hetil., 2016, 157(37), 1459-1468.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom